Cyclic urea derivatives, pharmaceutical compositions containing these
申请人:Karl Thomae GmbH
公开号:US05681841A1
公开(公告)日:1997-10-28
The invention relates to cyclic urea derivatives of general formula I ##STR1## wherein R.sub.a, R.sub.b, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation inhibiting effects, and to drugs containing the compounds and processes for preparing them.
A compound of formula (I): ##STR1## in which: R.sub.1, R.sub.2, which may be identical or different, represent hydrogen or halogen, or alkyl, alkoxy, nitro or trihalomethyl, X represents CO, SO.sub.2 or CH.sub.2, A.sub.1 represents any one of the groups as defined in the description, A.sub.2 represents --(CH.sub.2).sub.n or --CH.dbd.CH--, R.sub.3, R.sub.4, which may be identical or different, represent hydrogen or alkyl, its isomers as well as its addition salts with a pharmaceutically acceptable base and medicinal product containing the same are useful as angiogenesis inhibitors.
Vinylphosphonates have been widely utilized in organic synthesis during the last two decades. In this article, a novel, highly regioselective cycloaddition utilizing nitrileoxides and vinylphosphonate for the synthesis of isoxazoline and fused isoxazoline rings was developed. The method has the advantages in that it tolerates a wide variety of functional groups.